跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Pembrolizumab Solution for Infusion 25mg/mL - HSA Drug Approval Details
Approvals
/
HSA
/
Pembrolizumab Solution for Infusion 25mg/mL
Approved
THERAPEUTIC
Pembrolizumab Solution for Infusion 25mg/mL
MSD International GmbH T/A MSD Ireland (Carlow)
🇸🇬 Health Sciences Authority
Approval Date
Jan 13, 2023
Approval ID
47d49360a2fae815
Company
MSD International GmbH T/A MSD Ireland (Carlow)
Type
Therapeutic
Approval Details
Approval Id
47d49360a2fae815
Drug Name
Pembrolizumab Solution for Infusion 25mg/mL
Product Name
Pembrolizumab Solution for Infusion 25mg/mL
Approval Number
SIN16677P
Approval Date
2023-01-13
Registrant
MSD PHARMA (SINGAPORE) PTE. LTD.
Licence Holder
MSD PHARMA (SINGAPORE) PTE. LTD.
Drug Type
Therapeutic
Forensic Classification
Prescription Only
Dosage Form
INFUSION, SOLUTION CONCENTRATE
Route Of Administration
INTRAVENOUS
Atc Code
L01XC18
Atc Item Name
xl 01 xc 18
Pharma Manufacturer Name
MSD PHARMA (SINGAPORE) PTE. LTD.
Company Detail Path
/organization/msd-pharma-singapore-pte-ltd
Active Ingredients
Pembrolizumab
25.0mg/mL
PEMBROLIZUMAB
25 MG/ML
Approved
Quick Info
Agency
HSA
Country
🇸🇬
Approval Date
Jan 13, 2023
Approval ID
47d49360a2fae815
Type
Therapeutic
Back to HSA Approvals
